| Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. | Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs.
Lumeau A, Bery N, Francès A, Gayral M, Labrousse G, Ribeyre C, Lopez C, Nevot A, El Kaoutari A, Hanoun N, Sarot E, Perrier M, Pont F, Cerapio JP, Fournié JJ, Lopez F, Madrid-Mencia M, Pancaldi V, Pillaire MJ, Bergoglio V, Torrisani J, Dusetti N, Hoffmann JS, Buscail L, Lutzmann M, Cordelier P., Free PMC Article | 04/8/2024 |
| Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells. | Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells.
Hong KU, Tagnedji AH, Doll MA, Walls KM, Hein DW., Free PMC Article | 07/20/2023 |
| Seven-membered ring nucleobases as inhibitors of human cytidine deaminase and APOBEC3A. | Seven-membered ring nucleobases as inhibitors of human cytidine deaminase and APOBEC3A.
Kurup HM, Kvach MV, Harjes S, Jameson GB, Harjes E, Filichev VV., Free PMC Article | 06/28/2023 |
| A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD(.) | A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD().
Silveira SC, Buhagiar-Labarchède G, Onclercq-Delic R, Gemble S, Bou Samra E, Mameri H, Duchambon P, Machon C, Guitton J, Amor-Guéret M., Free PMC Article | 12/12/2020 |
| MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism. | MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism.
Olou AA, King RJ, Yu F, Singh PK., Free PMC Article | 11/28/2020 |
| Results of gemcitabine-induced neutropenia using a competing risk model in a prospective randomized clinical study has proposed a potentially novel mechanism of the protective effect of the CDA rs2072671 variant. | An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K., Free PMC Article | 04/25/2020 |
| data indicate that dominant negative effect of JP41 mutation on class-switch recombination (CSR) is likely due to the depletion of the CSR-specific RNA-binding proteins from WT activation-induced cytidine deaminase | Depletion of recombination-specific cofactors by the C-terminal mutant of the activation-induced cytidine deaminase causes the dominant negative effect on class switch recombination.
Al Ismail A, Husain A, Kobayashi M, Honjo T, Begum NA. | 01/26/2019 |
| SNPs in CDA and CES2 were associated with benefit from the addition of capecitabine to chemotherapy in metastatic breast cancer patients | Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Lam SW, van der Noort V, van der Straaten T, Honkoop AH, Peters GJ, Guchelaar HJ, Boven E. | 12/22/2018 |
| The observed incomplete sister chromatid disjunction may be due to the accumulation of unreplicated DNA during mitosis in CDA-deficient cells, as reflected in the changes in centromeric DNA structure associated with the decrease in basal PARP-1 activity. | Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity.
Gemble S, Buhagiar-Labarchède G, Onclercq-Delic R, Jaulin C, Amor-Guéret M., Free PMC Article | 03/31/2018 |
| Intracerebral microdialysis revealed that clonal NSC line to stably express cytosine deaminase (CD-NSCs) produced 5-FU locally in the brain in a 5-FC dose-dependent manner. Collectively, our results from this first-in-human study demonstrate initial safety and proof of concept regarding the ability of NSCs to target brain tumors and locally produce chemotherapy. | Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.
Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D'Apuzzo M, Metz MZ, Najbauer J, Bedell V, Vo T, Gutova M, Frankel P, Chen M, Aboody KS., Free PMC Article | 03/24/2018 |
| results indicate that rs2072671 in CDA may be an important prognostic marker in NK-AML patients. | Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.
Hyo Kim L, Sub Cheong H, Koh Y, Ahn KS, Lee C, Kim HL, Doo Shin H, Yoon SS. | 10/8/2016 |
| tumor cell lines that are susceptible to epigenetic nucleosides overexpress cytidine deaminase (CDA); CDA converts 5hmdC and 5fdC into variants of uridine that are incorporated into DNA, resulting in accumulation of DNA damage, and ultimately, cell death | CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.
Zauri M, Berridge G, Thézénas ML, Pugh KM, Goldin R, Kessler BM, Kriaucionis S., Free PMC Article | 05/7/2016 |
| RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. | RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P., Free PMC Article | 04/16/2016 |
| stimulation of PARP-1 activity in CDA-deficient cells restores replication and, thus, chromosome segregation. Moreover, increasing intracellular dCTP levels generates under-replication-induced sister-chromatid bridges as efficiently as PARP-1 knockdown | Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA.
Gemble S, Ahuja A, Buhagiar-Labarchède G, Onclercq-Delic R, Dairou J, Biard DS, Lambert S, Lopes M, Amor-Guéret M., Free PMC Article | 04/16/2016 |
| n the multivariate Cox regression analysis, we found that age at diagnosis, wild-type genotype of the CDA A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death | Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
Medina-Sanson A, Ramírez-Pacheco A, Moreno-Guerrero SS, Dorantes-Acosta EM, Sánchez-Preza M, Reyes-López A., Free PMC Article | 03/19/2016 |
| Single nucleotide polymorphisms in cytidine deaminase gene were associated with the efficacy of gemcitabine in Biliary Tract Cancer. | Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA, Woo SM, Hong EK, Jung MK, Park WS, Bae K, Han SS, Kim TH, Koh YH, Park SJ, Lee WJ. | 03/12/2016 |
| Polymorphisms in ABCB1, CDA, ENOSF1,and TYMS could help to predict specific and overall severe adverse reactions to capecitabine. | Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
García-González X, Cortejoso L, García MI, García-Alfonso P, Robles L, Grávalos C, González-Haba E, Marta P, Sanjurjo M, López-Fernández LA., Free PMC Article | 03/5/2016 |
| miR-484-modulated cytidine deaminase has a dual impact in promoting chemoresistance and suppressing cell proliferation in breast cancer | Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer.
Ye FG, Song CG, Cao ZG, Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, Yao L, Hu X, Shao ZM. | 01/30/2016 |
| This case report calls for further prospective studies investigating the exact role that CDA status plays in the clinical outcome of patients treated with azacytidine. | Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R. | 01/30/2016 |
| The A79C CDA polymorphism did not show a significant impact on the response rate to gemcitabine in NSCLC patients, while the wild type CDA genotype was indeed correlated to a lower rate of incidence of severe anemia in patients taking gemcitabine. | The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
Li H, Wang X, Wang X. | 07/4/2015 |
| These results suggest that CDA 79A>C polymorphisms is a potential biomarker for toxicity of gemcitabine-based chemotherapy and a CDA testing before gemcitabine administration is preferred. | Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X, Chen W, Fan H, Zhu B. | 04/11/2015 |
| These results provide suggestive evidence of a favorable effect for the XPD 312Asp/Asp and XPD 751Lys/Lys genotypes with respect to overall survival rates in platinum-treated NSCLC patients | Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M, Ding YJ, Feng Y, Zhang QR, Xiang Y, Wan HY. | 12/20/2014 |
| Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. | Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, Gil Z. | 09/20/2014 |
| The T70 variant has a lower catalytic efficiency toward the analyzed substrates when compared to the A70 variant, suggesting that patients carrying the 208G>A SNP may have a greater exposure to cytosine based pro drugs | Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.
Micozzi D, Carpi FM, Pucciarelli S, Polzonetti V, Polidori P, Vilar S, Williams B, Costanzi S, Vincenzetti S., Free PMC Article | 08/23/2014 |
| Carriers of the CDA*2B haplotype displayed higher CDA activity. | CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population.
Carpi FM, Vincenzetti S, Ubaldi J, Pucciarelli S, Polzonetti V, Micozzi D, Mignini F, Napolioni V. | 03/29/2014 |